SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of SL-11047 in treating patients with relapsed or refractory lymphoma.

Key facts

Study ID

NCT00293488

Run by

Progen Pharmaceuticals

People needed

20

Starts

2006-01-01

Last updated by the study team

2016-06-23

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.